Published 2002
| Version v1.0.0
Journal Article
Open
Atomoxetine Open-Label Trial in ADHD
Creators
Abstract
Atomoxetine (originally named tomoxetine), a new therapy for attention deficit hyperactivity disorder (ADHD) marketed by Eli Lilly, was compared to methylphenidate in a prospective, randomized, open-label study for 10 weeks duration, at the University of Nebraska Medical Center, Massachusetts General Hospital, Mount Sinai Medical Center, Carolinas Medical Center, and Lilly Research Laboratories.Files
PNB-16-54.pdf
Files
(2.9 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:c3e1862ea1de34e114df1717f11794e4
|
2.9 MB | Preview Download |
Additional details
Identifiers
- Other
- PNB-16-54
Dates
- Created
-
2002When the item was originally created.